and 786-0 CRISPR KO clones (100% vs 27%AE5.56%, respectively, p 0.05). The modified Boyden chamber assay also showed significant difference in productive cell migration between 786-0 scramble and 786-0 CRISPR KO clones (100% vs 42AE3.46%, respectively, p 0.05). Compared to 786-0 scramble clones, 786-0 CRISPR KO clones demonstrated significant reduction in extravasation on the avian embryo model (100% vs 46.33AE8.37%, respectively, p 0.05).
INTRODUCTION AND OBJECTIVES:
Renal cell carcinoma (RCC) is the most common malignancy of kidney, yet its molecular pathogenesis is poorly understood. We identified protein of relevant evolutionary and lymphoid interest domain containing 2 (PRELID2) as a novel clear cell RCC (ccRCC)-specific molecule through genome-wide expression profile analysis. To date, no reports have characterized the significance of transactivation of PRELID2 in clinical RCC progression. We here report the critical roles of a mitochondrial PRELID2 in renal carcinogenesis.
METHODS: We used siRNA oligonucleotides to knock down gene expression in two ccRCC cell lines, Caki-1 and 786O. We established PRELID2 stably transfected HEK-293 cell line. Cell viability was assessed by Cell Counting Kit-8 (DOJINDO) at 72hrs after transfection. The absorbance at 450 nm was measured using a multi-label counter infinite 200 (TECAN). Long-term cell proliferation was measured using by the IncuCyteÒ ZOOM system (Essen BioScience). Mitochondrial reactive oxygen species (ROS) production measured by flow cytometry using MitoSOX Red (Thermo Fisher scientific). Mitochondrial respiratory function measured using Seahorse XF Cell Mito Stress Test XF24 extracellular flux analyzer (Agilent). We also analyzed PRELID2 functions by RNA interference and mass spectrometry, and evaluated PRELID2 interaction protein using immunoprecipitation with PRELID2 and mass spectrometry.
RESULTS: DNA microarray, quantitative RT-PCR and TGCA database analyses showed significant upregulation of PRELID2 in ccRCC cases. Introduction of PRELID2 into HEK293 cells significantly enhanced cell growth, whereas knockdown of PRELID2 expression drastically suppressed growth in ccRCC cells. Notably, depletion of PRELID2 led to enhance ROS production, thereby causing increased oxidized proteins, in ccRCC cells. Extracellular flux analysis showed that downregulated of spare respiratory capacity in PRELID2-depleted cells. Furthermore, we found the interaction of HA-PRELID2 with endogenous PHB2 (Prohibitin 2), which is essential for mitochondrial morphogenesis and homeostasis, in ccRCC cells.
CONCLUSIONS: Our studies are the first to demonstrate that PRELID2 is likely to play a crucial role in renal carcinogenesis though its interacting with mitochondrial PHB2. TRIB3) is a member of the mammalian pseudokinase tribbles family and is involved in multiple biological processes. However, the role of TRIB3 in renal cell carcinoma (RCC) remains unclear. In this study, we aimed to elucidate the biological functions of TRIB3 in RCC and explore its underlying mechanisms.
METHODS: TRIB3 expression and its correlation with clinicopathological features was evaluated in 123 patients with RCC. A series of cytological experiments were performed to clarify the biological functions of TRIB3, and potential molecular regulatory mechanisms were explored using transcriptome sequencing. KEGG pathway analysis was used to clarify the physiological functions and signaling pathways related to the DEGs in RCC cell lines. Cells were cultured and treated with Cobalt chloride (CoCl 2 ) for 0 h, 2 h, 4 h, 6 h, 12 h, 24 h, 48 h or 72 h. Then, the expression of TRIB3, HIF-1a and HIF-2a was assessed. The HIF-1a promoter region was inserted into a pLVX basic vector. The Dual-Luciferase Reporter Assay System was used in the luciferase reporter assays.
RESULTS: TRIB3 expression was significantly elevated in RCC tissues compared to that in paracancerous tissues, and high expression of TRIB3 was correlated with both advanced tumor stage and unfavorable prognosis. TRIB3 knockdown markedly inhibited RCC cell proliferation, migration and invasion. Furthermore, overexpression of TRIB3 promoted RCC cell proliferation, migration, invasion and xenograft tumor growth. Notably, TRIB3 expression was modulated by hypoxia-inducible factor-1a (HIF-1a), which enhanced cell viability and invasiveness via targeting the MAPK signaling pathway.
CONCLUSIONS: This study reveals the potential oncogenic role of TRIB3 in RCC pathogenesis and illustrates the mechanisms underlying TRIB3-mediated tumor progression, providing new insight into the development of TRIB3 as a tumor biomarker and therapeutic target. METHODS: We analyzed SMYD3 expression in human RCC with Western blot and immunohistochemistry. SMYD3 expression was knocked down using short hairpin RNAs (shRNA). Cell proliferation, colony formation, apoptosis analyses and xenograft transplantation were performed to evaluate the impact of SMYD3 depletion on RCC cells. EGFR expression and promoter activity were determined using qPCR, western blot, and luciferase reporter assay. EGFR promoter association with Sp1, SMYD3, and histone modifications was assessed by chromatin immunoprecipitation.
RESULTS: We identified that SMYD3 promoted RCC development through directly activating EGFR at transcriptional level. We found that SMYD3 expression was elevated in RCC tissues and associated with tumor stage, histological grade, nuclear grade and oncological outcome. Depletion of SMYD3 inhibited RCC cell proliferation, colony formation, and xenograft tumor formation, and led cell apoptosis. Two functional SMYD3-binding motifs were identified in the EGFR promoter region. In addition, we validated the accumulation of SMYD3 and SP1 at the EGFR promoter binding site, thereby increasing the transcriptional activity of EGFR promoter through chromatin remodeling in RCC cells.
CONCLUSIONS: SMYD3 as a poor prognostic indicator promotes RCC malignant progression via direct activation of EGFR transcription and expression.
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MP16-10 EIF4E PHOSPHORYLATION INHIBITS METASTASIS IN CLEAR CELL RENAL CELL CARCINOMA
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INTRODUCTION AND OBJECTIVES: The eukaryotic initiation factor 4E (eIF4E) is a 5
0 -cap component binding to mRNA. It is regulated by two pathways; mTOR/4EBP1/eIF4E and MNK/eIF4E pathway. The mTOR/4EBP1/eIF4E pathway promotes cell proliferation and antiapoptotic behavior in clear cell renal cell carcinoma (ccRCC). This pathway does not affect eIF4E phosphorylation. Besides, MNKs phosphorylate eIF4E, which also promote translation in a different manner from Akt/mTOR pathway. However, the role of MNK pathway remains unknown in ccRCC. Our objectives are to investigate the role of eIF4E phosphorylation in ccRCC.
METHODS: Firstly, we evaluated phospho-eIF4E (p-eIF4E) expression in 290 localized RCC surgical specimens using immunohistochemistry (IHC) and compared the recurrence rate. Secondly, western blotting, scratch assay, and invasion assay in RCC cell lines were performed with or without MNK inhibition which suppresses phosphorylation of eIF4E. Lastly, MAPK family protein (ERK1/2, p38, and ERK5) and mTOR inhibitors were administered onto ccRCC cell lines, and estimated p-eIF4E status using WB, since previous reports in other cancers mentioned that MAPK family proteins activate MNKs and mTOR suppresses MNKs.
RESULTS: Patients with low expression of p-eIF4E has higher recurrence rate (p [ 0.024, Fig 1) , and low p-eIF4E expression was an independent indicator for ccRCC recurrence after nephrectomy. Inhibition of MNK using siRNA or MNK inhibitor up-regulated vimentin and N-cadherin expression which are involved in cell migration (Fig 2) . Scratch assay showed that MNK2 inhibition enhanced cell migration (Fig 3) . These results indicate that eIF4E phosphorylation suppresses migration and metastasis in ccRCC. In regard to regulation of MNKs, ERK5 inhibitor promoted phosphorylation of eIF4E, while ERK1/2 or p38 inhibitors did not affect it. mTOR inhibitor rapamycin also promote eIF4E phosphorylation (Fig 4) .
CONCLUSIONS: Low p-eIF4E is a biomarker for ccRCC recurrence after nephrectomy. Inhibition of eIF4E phosphorylation via MNK knockdown enhances ccRCC migration. ERK5 or mTOR inhibition could enhance eIF4E phosphorylation and be a promising strategy for prevention of ccRCC recurrence.
